165 related articles for article (PubMed ID: 35689378)
21. The impact of diuretic use and ABCG2 genotype on the predictive performance of a published allopurinol dosing tool.
Wright DFB; Dalbeth N; Phipps-Green AJ; Merriman TR; Barclay ML; Drake J; Tan P; Horne A; Stamp LK
Br J Clin Pharmacol; 2018 May; 84(5):937-943. PubMed ID: 29341237
[TBL] [Abstract][Full Text] [Related]
22. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout.
Wright DF; Stamp LK; Merriman TR; Barclay ML; Duffull SB; Holford NH
Eur J Clin Pharmacol; 2013 Jul; 69(7):1411-21. PubMed ID: 23475133
[TBL] [Abstract][Full Text] [Related]
23. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
Torres RJ; Puig JG
Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
[TBL] [Abstract][Full Text] [Related]
24. Individualising the dose of allopurinol in patients with gout.
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
[TBL] [Abstract][Full Text] [Related]
25. An audit of a therapeutic drug monitoring service for allopurinol therapy.
Kannangara DR; Ramasamy SN; Ray JE; Jones G; Graham GG; Williams KM; Day RO
Ther Drug Monit; 2013 Dec; 35(6):863-6. PubMed ID: 24263644
[TBL] [Abstract][Full Text] [Related]
26. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
[TBL] [Abstract][Full Text] [Related]
27. The
Lin CT; Chen IC; Chen YJ; Lin YC; Chang JC; Wang TJ; Huang WN; Chen YH; Chen YH; Lin CH; Chen YM
Front Endocrinol (Lausanne); 2023; 14():1074012. PubMed ID: 36967798
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects.
Turnheim K; Krivanek P; Oberbauer R
Br J Clin Pharmacol; 1999 Oct; 48(4):501-9. PubMed ID: 10583019
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response.
Wen CC; Yee SW; Liang X; Hoffmann TJ; Kvale MN; Banda Y; Jorgenson E; Schaefer C; Risch N; Giacomini KM
Clin Pharmacol Ther; 2015 May; 97(5):518-25. PubMed ID: 25676789
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
[TBL] [Abstract][Full Text] [Related]
31. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.
Liu X; Ni XJ; Shang DW; Zhang M; Hu JQ; Qiu C; Luo FT; Wen YG
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 941():10-6. PubMed ID: 24184830
[TBL] [Abstract][Full Text] [Related]
32. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus.
Zaidi F; Narang RK; Phipps-Green A; Gamble GG; Tausche AK; So A; Riches P; Andres M; Perez-Ruiz F; Doherty M; Janssen M; Joosten LAB; Jansen TL; Kurreeman F; Torres RJ; McCarthy GM; Miner JN; Stamp LK; Merriman TR; Dalbeth N
Rheumatology (Oxford); 2020 Sep; 59(9):2544-2549. PubMed ID: 31998961
[TBL] [Abstract][Full Text] [Related]
33. Orotidine accumulation in human erythrocytes during allopurinol therapy: association with high urinary oxypurinol-7-riboside concentrations in renal failure and in the Lesch-Nyhan syndrome.
Simmonds HA; Reiter S; Davies PM; Cameron JS
Clin Sci (Lond); 1991 Mar; 80(3):191-7. PubMed ID: 1850677
[TBL] [Abstract][Full Text] [Related]
34. Association between serum uric acid related genetic loci and diabetic kidney disease in the Chinese type 2 diabetes patients.
Yan D; Wang J; Jiang F; Zhang R; Sun X; Wang T; Wang S; Peng D; He Z; Bao Y; Hu C; Jia W
J Diabetes Complications; 2016 Jul; 30(5):798-802. PubMed ID: 26993665
[TBL] [Abstract][Full Text] [Related]
35. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
[TBL] [Abstract][Full Text] [Related]
36. Allopurinol and oxypurinol in human breast milk.
Kamilli I; Gresser U
Clin Investig; 1993 Feb; 71(2):161-4. PubMed ID: 8461629
[TBL] [Abstract][Full Text] [Related]
37. Females present higher dose-adjusted drug concentrations of metoprolol and allopurinol/oxypurinol than males.
Hindi J; Pilon MO; Meloche M; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
Clin Transl Sci; 2023 May; 16(5):872-885. PubMed ID: 36864560
[TBL] [Abstract][Full Text] [Related]
38. Association of ABCG2 rs2231142-A allele and serum uric acid levels in male and obese individuals in a Han Taiwanese population.
Cheng ST; Wu S; Su CW; Teng MS; Hsu LA; Ko YL
J Formos Med Assoc; 2017 Jan; 116(1):18-23. PubMed ID: 26792383
[TBL] [Abstract][Full Text] [Related]
39. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
Wright DF; Doogue MP; Barclay ML; Chapman PT; Cross NB; Irvine JH; Stamp LK
Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
[TBL] [Abstract][Full Text] [Related]
40. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
